Cellebrite DI Ltd. (NASDAQ:CLBT – Get Free Report) has been given a consensus rating of “Buy” by the six research firms that are presently covering the company, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy recommendation. The average 1-year target price among analysts that have issued a report on the stock in the last year is $14.20.
Several brokerages have issued reports on CLBT. Lake Street Capital started coverage on Cellebrite DI in a research note on Friday, April 19th. They issued a “buy” rating and a $13.00 target price on the stock. Needham & Company LLC boosted their price objective on Cellebrite DI from $13.50 to $14.00 and gave the company a “buy” rating in a research note on Friday, May 24th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Cellebrite DI from $14.00 to $15.00 and gave the company an “overweight” rating in a report on Wednesday.
Check Out Our Latest Stock Analysis on CLBT
Institutional Trading of Cellebrite DI
Cellebrite DI Price Performance
Shares of NASDAQ:CLBT opened at $13.94 on Friday. The company has a market capitalization of $2.87 billion, a PE ratio of -24.03, a price-to-earnings-growth ratio of 1.84 and a beta of 1.50. Cellebrite DI has a 1 year low of $6.36 and a 1 year high of $14.11. The business has a fifty day moving average price of $12.45 and a two-hundred day moving average price of $11.48.
Cellebrite DI (NASDAQ:CLBT – Get Free Report) last released its earnings results on Thursday, May 23rd. The company reported $0.08 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.02. The firm had revenue of $89.60 million during the quarter, compared to the consensus estimate of $85.34 million. Cellebrite DI had a negative net margin of 32.57% and a positive return on equity of 417.94%. The company’s revenue was up 25.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.03 EPS. Sell-side analysts anticipate that Cellebrite DI will post 0.34 earnings per share for the current year.
Cellebrite DI Company Profile
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Further Reading
- Five stocks we like better than Cellebrite DI
- What is a Low P/E Ratio and What Does it Tell Investors?
- Brinker International’s Price Dip is an Appetizing Entry Point
- Stock Market Upgrades: What Are They?
- 3 Stocks That Could Beat the September Blues
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Canopy Growth Stock: Can It Sustain Recent Gains?
Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.